Regenera Pharma is a clinical-stage pharmaceutical company developing innovative drugs for the treatment of optic nerve neuropathies. The company is currently focused on a treatment for ischemic optic neuropathy.
Regenera will conduct a phase 3 study in the U.S. for evaluating the efficacy and safety of RPh201 treatment in participants diagnosed with NAION. It will also commence a phase 2 study in Canada that will evaluate the safety, tolerability, and clinical benefit of RPh201 in individuals with Alzheimers disease, with or without coexisting cerebrovascular disease.
Regenera collaborates with the Henry Ford Health System to investigate the therapeutic effects of RPh201 on stroke recovery in a rat model of embolic middle cerebral artery occlusion (MCAO).
Cumulative Funding Raised Over Time ($)
Employees Over Time
Regenera Pharma Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Nov 16, 2020
www.calcalist.co.il
המחוזי מינה נאמן לחברת הסטארט-אפ ריגנרה פארמה
#Investment
May 14, 2019
www.globenewswire.com
Regenera Announces Publication of RPh201 Phase 2a Study Data for the Treatment of NAION in the Journal of Neuro-Ophthalmology
#Customers
Aug 2, 2018
www.prnewswire.com
Regenera Pharma Enrolls First Patient in US Phase 3 Study of RPh201 in NAION, Advances Phase 2 Study in Alzheimer's Disease in Canada